Fig. 3From: CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancersSurvival analysis of matrix metalloproteinase 9 (MMP-9) expression in CD68+ and CD163+ tumor-associated macrophages (TAMs) based on estrogen receptor (ER) status. Kaplan–Meier curves of MMP-9 expression in CD163+ TAMs (upper panel) in ER-positive (a) and ER-negative (b) cases of cohort A and triple-negative breast cancer (TNBC) cohort B (c). Kaplan–Meier curves of MMP-9 expression in CD68+ TAMs (lower panel) in ER-positive (d) and ER-negative (e) cases of cohort A and TNBC cohort B (f)Back to article page